Navigation Links
Manchester Announces Availability of Chenodal(TM)

FORT COLLINS, Colo., Dec. 14 /PRNewswire/ -- Manchester Pharmaceuticals, Inc.(TM) announced today the availability of Chenodal(TM) 250 mg (chenodiol tablets). On October 22, 2009, the US Food and Drug Administration (FDA) approved Chenodal, an important therapy for patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Chenodal prescriptions have started to be dispensed to patients exclusively through Centric Health Resources ("Centric"), a specialty pharmacy company. Centric provides a single point of contact to deliver seamless support for Chenodal including providing necessary information to health care providers, patients and families, assisting with reimbursement and insurance issues, and ensuring that Chenodal reaches the patients who need it as fast and as conveniently as possible. Patients and physicians are encouraged to contact Centric now at 1-866-758-7068 to begin the process of setting up their first order of Chenodal or to obtain more information about Chenodal. Centric Customer Service is available Monday through Friday 7:00 AM to 6:00 PM CST.

"The commercial availability of Chenodal now provides doctors and their patients with a chenodiol product that meets all FDA requirements for product integrity, quality, safety and effectiveness," commented Lloyd Glenn, Manchester's President.

About Manchester:

Manchester Pharmaceuticals, a privately-held specialty pharmaceutical company, is focused on the identification, development and commercialization of new therapeutic modalities to address the special needs of patients with rare diseases. Manchester is actively pursuing the license and acquisition of additional new product opportunities in the rare disease area.

    For more information:
    Lloyd Glenn, President

SOURCE Manchester Pharmaceuticals, Inc.

SOURCE Manchester Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology:
(Date:10/13/2015)... Alexandria, Va. — , ... ... Military Officers Association of America (MOAA) will hold its 2015 ... Highlights include a free military career fair; informational seminars; a ... chairman of the Joint Chiefs of Staff; and the Community ...
(Date:10/13/2015)... ... October 13, 2015 , ... Vision Group Holdings, the ... San Diego, California. With brands including The LASIK Vision Institute and TLC Laser Eye ... the nationwide leader in laser vision correction. , Global Laser Vision will continue to ...
(Date:10/13/2015)... Nashville, Tennessee (PRWEB) , ... October 13, 2015 ... ... owned leader of anesthesia and pain management services, today announced its partnership with ... the partnership integrates data from disparate systems and organizes the data into an ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded design services ... the industry’s first RGB-IR pixel format camera with a USB 3.0 interface and ... family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a ...
Breaking Medicine News(10 mins):